Genovis was granted SEK 1 million in research support from VINNOVA

Pharmaceutical companies have a constant need to improve their ability to understand their process parameters and the parameters that give rise to or affect the properties of biological drugs*. The ultimate goal is to control the process by analyzing the product at different times and adjusting process parameters when necessary to achieve a safe and effective biological drug as the end product.

“In addition to patient safety, the pharmaceutical industry is interested in being able to produce high-quality drugs at the lowest cost possible and the project specifically intends to offer this group a reliable and automatic method that saves both time and money in the customer’s optimization of production processes,” says Sarah Fredriksson, CEO at Genovis

*Biological drugs are produced in “living” cells, a production system that is far more complex than pure chemical synthesis of small molecules. The industry has a strong incentive to find rapid and automatable solutions to analyze antibodies – preferably one that is fully automated, without any manual intervention.